Your browser is no longer supported. Please, upgrade your browser.
SPRB [NASD]
Spruce Biosciences, Inc.
Index- P/E- EPS (ttm)-1.79 Insider Own0.02% Shs Outstand23.37M Perf Week-13.08%
Market Cap53.43M Forward P/E- EPS next Y-2.41 Insider Trans0.00% Shs Float4.09M Perf Month-42.35%
Income-41.40M PEG- EPS next Q-0.48 Inst Own- Short Float29.74% Perf Quarter-49.67%
Sales- P/S- EPS this Y-125.70% Inst Trans0.18% Short Ratio0.31 Perf Half Y-76.24%
Book/sh5.12 P/B0.44 EPS next Y-26.20% ROA-27.80% Target Price11.00 Perf Year-88.75%
Cash/sh3.91 P/C0.58 EPS next 5Y- ROE-30.70% 52W Range2.25 - 28.49 Perf YTD-49.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-92.07% Beta-
Dividend %- Quick Ratio10.40 Sales past 5Y- Gross Margin- 52W Low0.44% ATR0.60
Employees19 Current Ratio10.40 Sales Q/Q- Oper. Margin- RSI (14)34.60 Volatility12.00% 14.46%
OptionableNo Debt/Eq0.04 EPS Q/Q-13.80% Profit Margin- Rel Volume0.15 Prev Close2.48
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume3.95M Price2.26
Recom2.10 SMA20-36.27% SMA50-30.30% SMA200-72.03% Volume610,872 Change-8.87%
Dec-17-21Initiated Oppenheimer Outperform $15
Dec-10-21Initiated The Benchmark Company Speculative Buy $7
Nov-16-21Downgrade SVB Leerink Outperform → Mkt Perform
Jul-19-21Initiated H.C. Wainwright Buy $30
Apr-26-21Resumed Credit Suisse Outperform $26
Nov-03-20Initiated SVB Leerink Outperform $35
Nov-03-20Initiated RBC Capital Mkts Outperform $28
Nov-03-20Initiated Credit Suisse Outperform $28
Nov-03-20Initiated Cowen Outperform $44
Jan-24-22 08:00AM  
Jan-19-22 09:38PM  
Jan-05-22 08:00AM  
Dec-31-21 01:50PM  
Dec-17-21 07:27AM  
07:16AM  
Dec-14-21 10:00AM  
Nov-18-21 04:05PM  
Nov-15-21 04:05PM  
04:01PM  
Sep-29-21 01:06PM  
Sep-07-21 04:05PM  
Aug-25-21 09:00AM  
Aug-11-21 08:55AM  
Aug-10-21 04:05PM  
11:59AM  
Jul-23-21 10:14AM  
Jul-07-21 11:38AM  
Jun-24-21 08:07AM  
08:02AM  
Jun-21-21 08:03AM  
May-24-21 08:01AM  
May-13-21 04:05PM  
May-12-21 04:05PM  
Mar-22-21 04:05PM  
Mar-17-21 08:00AM  
Mar-02-21 08:00AM  
Feb-17-21 04:05PM  
Jan-12-21 05:10AM  
Jan-06-21 08:00AM  
Dec-17-20 04:05PM  
Nov-18-20 04:05PM  
Nov-04-20 04:05PM  
Oct-16-20 07:38PM  
Oct-14-20 04:05PM  
Oct-09-20 03:49PM  
01:28PM  
11:51AM  
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIMPSON CAMILLA VDirectorMay 20Option Exercise0.85334284334May 21 09:10 PM
SIMPSON CAMILLA VDirectorMay 20Sale15.293345,1070May 21 09:10 PM
Novo Holdings A/S10% OwnerMay 19Sale13.90475,0006,602,5004,514,336May 21 04:32 PM
SIMPSON CAMILLA VDirectorApr 30Option Exercise0.8514,04511,93814,045May 04 09:09 PM
SIMPSON CAMILLA VDirectorApr 30Sale16.1414,045226,6640May 04 09:09 PM